{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:34:31Z","timestamp":1785411271134,"version":"3.56.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.pharmthera.2017.10.015","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T02:16:57Z","timestamp":1510107417000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["G protein-coupled receptors as anabolic drug targets in osteoporosis"],"prefix":"10.1016","volume":"184","author":[{"given":"Natalie","family":"Diepenhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pastoureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Sabatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Langmead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2017.10.015_bb0005","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1083\/jcb.201008012","article-title":"Control of bone formation by the serpentine receptor Frizzled-9","volume":"192","author":"Albers","year":"2011","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0010","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1359\/jbmr.1997.12.3.384","article-title":"An intact N terminus is required for the anabolic action of parathyroid hormone on adult female rats","volume":"12","author":"Armamento-Villareal","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00198-008-0815-8","article-title":"Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants","volume":"20","author":"Bain","year":"2009","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"Wnt signaling in bone homeostasis and disease: From human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bone.2007.08.043","article-title":"Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro","volume":"42","author":"Bonnelye","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0030","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bone.2010.01.383","article-title":"Implication of the calcium sensing receptor and the phosphoinositide 3-kinase\/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells","volume":"46","author":"Boudot","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0035","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0040","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1476-5381.2009.00305.x","article-title":"Osteoblasts play key roles in the mechanisms of action of strontium ranelate","volume":"157","author":"Brennan","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.beem.2013.02.006","article-title":"Role of the calcium-sensing receptor in extracellular calcium homeostasis","volume":"27","author":"Brown","year":"2013","journal-title":"Best Practice & Research. Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0050","series-title":"Hypoparathyroidism","article-title":"Control of parathyroid hormone secretion by extracellular Ca2+","author":"Brown","year":"2015"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0055","doi-asserted-by":"crossref","first-page":"14051","DOI":"10.1074\/jbc.M500030200","article-title":"The trap-like relaxin-binding site of the leucine-rich G-protein-coupled receptor 7","volume":"280","author":"Bullesbach","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bone.2013.05.021","article-title":"Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women","volume":"56","author":"Caltabiano","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0065","doi-asserted-by":"crossref","first-page":"15718","DOI":"10.1074\/jbc.M112.344994","article-title":"A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo","volume":"287","author":"Carroll","year":"2012","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1210\/me.2014-1129","article-title":"Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor","volume":"29","author":"Carter","year":"2015","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/mol.109.063347","article-title":"Strontium Ranelate decreases receptor activator of nuclear factor-\u03baB ligand-induced osteoclastic differentiation in vitro: Involvement of the calcium-sensing receptor","volume":"78","author":"Caudrillier","year":"2010","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0080","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bcp.2007.04.020","article-title":"The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation","volume":"74","author":"Chattopadhyay","year":"2007","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0085","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1210\/en.2003-1127","article-title":"Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts","volume":"145","author":"Chattopadhyay","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0090","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jbmr.2074","article-title":"Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: Randomized comparison to alendronate","volume":"29","author":"Chavassieux","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0095","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrendo.2015.139","article-title":"PTH receptor-1 signalling\u2014Mechanistic insights and therapeutic prospects","volume":"11","author":"Cheloha","year":"2015","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0100","series-title":"Transplantation proceedings","first-page":"3554","article-title":"Cinacalcet improves bone density in post\u2013kidney transplant hyperparathyroidism","author":"Cho","year":"2010"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10059-012-0186-z","article-title":"Constitutive activation of smoothened leads to impaired developments of postnatal bone in mice","volume":"34","author":"Cho","year":"2012","journal-title":"Molecules and Cells"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bph.12937","article-title":"Biased allosteric modulation at the CaSR engendered by structurally diverse calcimimetics","volume":"172","author":"Cook","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0115","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-013-2582-4","article-title":"Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: A nested case\u2013control study in the CPRD","volume":"25","author":"Cooper","year":"2014","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1503\/cmaj.050929","article-title":"Parathyroid hormone for the treatment of osteoporosis: A systematic review","volume":"175","author":"Cranney","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0125","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S8756-3282(01)00419-7","article-title":"Incorporation and distribution of strontium in bone","volume":"28","author":"Dahl","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/BF01114813","article-title":"The effect of extracellular calcium elevation on morphology and function of isolated rat osteoclasts","volume":"9","author":"Datta","year":"1989","journal-title":"Bioscience Reports"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0140","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1210\/en.2011-1426","article-title":"Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor","volume":"153","author":"Davey","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13697137.2017.1289659","article-title":"The quest for new drugs to prevent osteoporosis-related fractures","volume":"20","author":"de Villiers","year":"2017","journal-title":"Climacteric"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0150","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1210\/me.2007-0274","article-title":"Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH\/PTHrP receptor","volume":"22","author":"Dean","year":"2008","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0155","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clinical Proceedures"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0160","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/jbmr.520","article-title":"Osteoblast extracellular Ca2+-sensing receptor regulates bone development, mineralization, and turnover","volume":"26","author":"Dvorak-Ewell","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0165","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nbt0616-580b","article-title":"Amgen\/UCB build on bone franchise with anti-sclerostin antibody","volume":"34","author":"Elvidge","year":"2016","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0170","series-title":"EMA\/84749\/2014","article-title":"European medicines agency recommends that Protelos\/Oressor remain available but with further restrictions","year":"2014"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0175","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nchembio.545","article-title":"Retromer terminates the generation of cAMP by internalized PTH-receptors","volume":"7","author":"Feinstein","year":"2011","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0180","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1359\/jbmr.080204","article-title":"Mutations in the insulin-like factor 3 receptor are associated with osteoporosis","volume":"23","author":"Ferlin","year":"2008","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029733","article-title":"Profiling insulin like factor 3 (INSL3) signaling in human osteoblasts","volume":"6","author":"Ferlin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0190","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nchembio.206","article-title":"Sustained cyclic AMP production by parathyroid hormone receptor endocytosis","volume":"5","author":"Ferrandon","year":"2009","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jbmr.554","article-title":"Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women","volume":"27","author":"Fitzpatrick","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0200","first-page":"2739","article-title":"Comparison of the biochemical responses to human parathyroid hormone-(1\u221231)NH2 and hPTH-(1-34) in healthy humans","volume":"84","author":"Fraher","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0205","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jcb.10369","article-title":"Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways","volume":"88","author":"Franceschi","year":"2003","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0210","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1093\/hmg\/8.10.1947","article-title":"Williams-Beuren syndrome: Genes and mechanisms","volume":"8","author":"Francke","year":"1999","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0215","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/endo.137.9.8756555","article-title":"Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion","volume":"137","author":"Freichel","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1359\/jbmr.1999.14.2.163","article-title":"Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats","volume":"14","author":"Frolik","year":"1999","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0225","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/j.1582-4934.2008.00673.x","article-title":"Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate","volume":"13","author":"Fromigu\u00e9","year":"2009","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/endo.130.1.1727705","article-title":"Structure-function relationship of parathyroid hormone: Activation of phospholipase-C, protein kinase-a and -C in osteosarcoma cells","volume":"130","author":"Fujimori","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0235","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jbmr.5650080414","article-title":"Protein kinase C-activating domains of parathyroid hormone-related protein","volume":"8","author":"Gagnon","year":"1993","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0240","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1101\/gad.13.6.709","article-title":"Wnt3a\u2212\/\u2212-like phenotype and limb deficiency in Lef1\u2212\/\u2212 Tcf1\u2212\/\u2212 mice","volume":"13","author":"Galceran","year":"1999","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0245","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1210\/endo.137.9.8756569","article-title":"Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH\/PTHrP receptors","volume":"137","author":"Gardella","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0250","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13662","article-title":"Structural mechanism of ligand activation in human calcium-sensing receptor","volume":"5","author":"Geng","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0255","doi-asserted-by":"crossref","first-page":"10856","DOI":"10.1074\/jbc.M513380200","article-title":"Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1\/2 activation","volume":"281","author":"Gesty-Palmer","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0260","first-page":"1ra1","article-title":"A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation","volume":"1","author":"Gesty-Palmer","year":"2009","journal-title":"Scientific and Translational Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0265","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.424","article-title":"Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes","volume":"26","author":"Gharibi","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0270","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0275","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI9038","article-title":"Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats","volume":"105","author":"Gowen","year":"2000","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0280","first-page":"746","article-title":"Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: In vivo and in vitro evidence","volume":"18","author":"Graham","year":"2009","journal-title":"Experimental Opinions in Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0285","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s00223-003-0155-9","article-title":"Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate","volume":"74","author":"Grey","year":"2004","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0290","doi-asserted-by":"crossref","first-page":"11717","DOI":"10.1073\/pnas.1120068109","article-title":"Wnt pathway inhibition via the targeting of frizzled receptors results in decreased growth and tumorigenicity of human tumors","volume":"109","author":"Gurney","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0295","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nature01660","article-title":"Control of osteoblast function and regulation of bone mass","volume":"423","author":"Harada","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0300","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/jcem-69-4-843","article-title":"Pulse amplitude and frequency modulation of parathyroid hormone in plasma","volume":"69","author":"Harms","year":"1989","journal-title":"Journal of Clinical Endocrinolocial and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0305","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2012.11.045","article-title":"Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis","volume":"53","author":"Henriksen","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0310","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00223-013-9741-7","article-title":"Osteoclast-derived coupling factors in bone remodeling","volume":"94","author":"Henriksen","year":"2014","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0315","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/14728222.2015.1045415","article-title":"Novel targets for the prevention of osteoporosis-lessons learned from studies of metabolic bone disorders","volume":"19","author":"Henriksen","year":"2015","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0320","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S8756-3282(96)00230-X","article-title":"Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo","volume":"19","author":"Hilliker","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0325","series-title":"Seminars in cell & developmental biology","first-page":"513","article-title":"Physiological and pathological actions of sphingosine 1-phosphate","author":"Hla","year":"2004"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0330","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1359-6446(05)03370-2","article-title":"Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors","volume":"10","author":"Hoare","year":"2005","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0335","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1359\/jbmr.2000.15.3.605","article-title":"The discrepancy between the binding affinity of PTH (1-34) and RS 66271 is explained by interaction of the PTH\/PTHrP receptor with G-protein","volume":"15","author":"Hoare","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0340","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1359\/jbmr.040907","article-title":"Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6","volume":"19","author":"Holmen","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0345","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","article-title":"The druggable genome","volume":"1","author":"Hopkins","year":"2002","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0350","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/jbmr.1978","article-title":"A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study","volume":"28","author":"Horwitz","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0355","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1210\/jc.2009-0233","article-title":"Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: Defining the maximal tolerable dose","volume":"95","author":"Horwitz","year":"2010","journal-title":"Journal of Clinical and Endocrinological Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0360","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jc.2002-021122","article-title":"Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis","volume":"88","author":"Horwitz","year":"2003","journal-title":"Journal of Clinical and Endocrinological Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0365","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1359\/jbmr.1997.12.12.1959","article-title":"Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells","volume":"12","author":"House","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2004-5-7-234","article-title":"The frizzled family: Receptors for multiple signal transduction pathways","volume":"5","author":"Huang","year":"2004","journal-title":"Genome Biology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0375","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1074\/jbc.M801668200","article-title":"The calcium-sensing receptor is involved in strontium Ranelate-induced osteoclast apoptosis: New insights into the associated signaling pathways","volume":"284","author":"Hurtel-Lemaire","year":"2009","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0380","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5414\/CN107052","article-title":"Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism","volume":"76","author":"Ishimura","year":"2011","journal-title":"Clinical Nephrology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1126\/science.1222879","article-title":"Structural basis of Wnt recognition by frizzled","volume":"337","author":"Janda","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0390","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0395","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tem.2012.10.003","article-title":"LRP5 and LRP6 in development and disease","volume":"24","author":"Joiner","year":"2013","journal-title":"Trends in Endocrinological Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0400","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/bbrc.1998.8448","article-title":"Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells","volume":"245","author":"Kameda","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0405","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/bbrc.1999.0932","article-title":"High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells","volume":"261","author":"Kanatani","year":"1999","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0410","doi-asserted-by":"crossref","first-page":"E915","DOI":"10.1152\/ajpendo.00315.2009","article-title":"The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion","volume":"297","author":"Kantham","year":"2009","journal-title":"American Journal of Physiological and Endocrinological Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0415","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/hmg\/ddi370","article-title":"Cannabinoid receptor type 2 gene is associated with human osteoporosis","volume":"14","author":"Karsak","year":"2005","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0420","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6215","article-title":"Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts","volume":"5","author":"Keller","year":"2014","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0425","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/pr.108.000992","article-title":"Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery","volume":"62","author":"Kenakin","year":"2010","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0430","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1210\/en.2006-1086","article-title":"The low-density lipoprotein class a module of the relaxin receptor (leucine-rich repeat containing G-protein coupled receptor 7): Its role in signaling and trafficking to the cell membrane","volume":"148","author":"Kern","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0435","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends in Endocrinology and Metabolism"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.10.015_bb0440","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jb\/mvv124","article-title":"Regulation of bone metabolism by Wnt signals","volume":"159","author":"Kobayashi","year":"2015","journal-title":"Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0445","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/jpet.117.241117","article-title":"TRV0109101, a G protein-biased agonist of the \u03bcOpioid receptor, does not promote opioid-induced mechanical allodynia following chronic administration","volume":"362","author":"Koblish","year":"2017","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2010.02.003","article-title":"Membrane receptors: Structure and function of the relaxin family peptide receptors","volume":"320","author":"Kong","year":"2010","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0455","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signaling","volume":"116","author":"Krishnan","year":"2006","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0460","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1681\/ASN.2010020186","article-title":"The regulation of parathyroid hormone secretion and synthesis","volume":"22","author":"Kumar","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0465","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10549-013-2779-4","article-title":"Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties","volume":"143","author":"Kundu","year":"2014","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0470","series-title":"Endocrine Society's 98th annual meeting and expo","author":"Langdahl","year":"2016"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0475","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1172\/JCI6629","article-title":"Ablation of the PTHrP gene or the PTH\/PTHrP receptor gene leads to distinct abnormalities in bone development","volume":"104","author":"Lanske","year":"1999","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0480","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1124\/jpet.109.156398","article-title":"Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands","volume":"331","author":"Leduc","year":"2009","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0485","doi-asserted-by":"crossref","first-page":"33086","DOI":"10.1074\/jbc.M705194200","article-title":"Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis","volume":"282","author":"Li","year":"2007","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0490","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature22327","article-title":"Phase-plate cryo-EM structure of a class B GPCR\u2013G-protein complex","volume":"546","author":"Liang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0495","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ndt\/gfh829","article-title":"Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism","volume":"20","author":"Lien","year":"2005","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0500","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jbmr.2382","article-title":"Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the Ovariectomized rat model of postmenopausal bone loss","volume":"30","author":"Liu","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0505","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1172\/JCI57407","article-title":"PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor","volume":"122","author":"Loupy","year":"2012","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0510","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1210\/me.2005-0169","article-title":"A docking site for G protein betagamma subunits on the parathyroid hormone 1 receptor supports signaling through multiple pathways","volume":"20","author":"Mahon","year":"2006","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0515","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00223001102","article-title":"Prostaglandin E 2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor","volume":"67","author":"Mano","year":"2000","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0520","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/s00198-004-1753-8","article-title":"Strontium ranelate: A novel mode of action optimizing bone formation and resorption","volume":"16","author":"Marie","year":"2005","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0525","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bone.2009.07.082","article-title":"The calcium-sensing receptor in bone cells: A potential therapeutic target in osteoporosis","volume":"46","author":"Marie","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0530","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1172\/JCI26239","article-title":"Osteoblast-derived PTHrP is a physiological regulator of bone formation","volume":"115","author":"Martin","year":"2005","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0535","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jbmr.3042","article-title":"Abaloparatide is an anabolic, but does it spare resorption?","volume":"32","author":"Martin","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00096-4","article-title":"Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: A phase 1 safety and pharmacokinetics study","volume":"2","author":"Martinelli","year":"2015","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric modulation of G protein-coupled receptors","volume":"47","author":"May","year":"2007","journal-title":"Annual Reviews in Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0550","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1096\/fj.06-6304fje","article-title":"The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis","volume":"20","author":"Mentaverri","year":"2006","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0555","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0560","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0565","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0570","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB 1 cannabinoid receptor agonists and antagonists: Focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Practice & Research. Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0575","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm.3654","article-title":"Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures","volume":"20","author":"Mov\u00e9rare-Skrtic","year":"2014","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0580","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/ml2002423","article-title":"Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened","volume":"3","author":"Munchhof","year":"2012","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0585","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V120.21.331.331","article-title":"Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: Results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression","volume":"120","author":"Munshi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0590","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0960-9822(99)80018-9","article-title":"Sonic hedgehog signaling by the patched\u2013smoothened receptor complex","volume":"9","author":"Murone","year":"1999","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0595","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0600","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2174\/1381612023393387","article-title":"Pharmacological regulation of parathyroid hormone secretion","volume":"8","author":"Nemeth","year":"2002","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0605","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","article-title":"Calcimimetic and Calcilytic drugs: Feats, flops, and futures","volume":"98","author":"Nemeth","year":"2016","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0610","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.beem.2013.02.008","article-title":"Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders","volume":"27","author":"Nemeth","year":"2013","journal-title":"Best Practice & Research Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0615","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/mol.116.105015","article-title":"Role of the second extracellular loop of the adenosine A1 receptor on allosteric modulator binding, signaling, and cooperativity","volume":"90","author":"Nguyen","year":"2016","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0620","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1086\/382196","article-title":"Homozygous Wnt3 mutation causes tetra-amelia in a large consanguineous family","volume":"74","author":"Niemann","year":"2004","journal-title":"The American Journal of Human Genetics"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0625","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jbmr.228","article-title":"CB2 cannabinoid receptor targets mitogenic Gi protein\u2013cyclin D1 axis in osteoblasts","volume":"26","author":"Ofek","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0630","doi-asserted-by":"crossref","first-page":"16525","DOI":"10.1073\/pnas.0808750105","article-title":"Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation","volume":"105","author":"Okazaki","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0635","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/374350a0","article-title":"Dorsalizing signal Wnt-7a required for normal polarity of DV and AP axes of mouse limb","volume":"374","author":"Parr","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0640","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0645","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1021\/jm970181o","article-title":"Conformational studies of RS-66271, an analog of parathyroid hormone-related protein with pronounced bone anabolic activity","volume":"40","author":"Pellegrini","year":"1997","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0650","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bone.2007.11.017","article-title":"Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation","volume":"42","author":"Pettway","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0655","first-page":"1325","article-title":"Interaction between osteoblast and osteoclast: Impact in bone disease","volume":"19","author":"Phan","year":"2004","journal-title":"Histology and Histopathology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0660","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0665","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tem.2004.01.006","article-title":"Parathyroid hormone: A double-edged sword for bone metabolism","volume":"15","author":"Qin","year":"2004","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0670","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3965","article-title":"Structural insights into the role of the smoothened cysteine-rich domain in hedgehog signalling","volume":"4","author":"Rana","year":"2013","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0675","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd3478","article-title":"Trends in the exploitation of novel drug targets","volume":"10","author":"Rask-Andersen","year":"2011","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0680","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0685","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study","volume":"90","author":"Reginster","year":"2005","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0690","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrneph.2016.59","article-title":"Localization and function of the renal calcium-sensing receptor","volume":"12","author":"Riccardi","year":"2016","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0695","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/jbmr.5650090807","article-title":"Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase","volume":"9","author":"Rixon","year":"1994","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0700","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF02196199","article-title":"The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats","volume":"6","author":"Russell","year":"1970","journal-title":"Calcified Tissue Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0705","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1038\/sj.emboj.7601430","article-title":"Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast\u2013osteoblast coupling","volume":"25","author":"Ryu","year":"2006","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0710","first-page":"243","article-title":"PTH and PTHrP: Similar structures but different functions","volume":"14","author":"Schluter","year":"1999","journal-title":"News in Physiological Sciences"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0715","doi-asserted-by":"crossref","first-page":"34942","DOI":"10.1074\/jbc.M602728200","article-title":"Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class a modules","volume":"281","author":"Scott","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0720","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00198-002-1340-9","article-title":"Reduced bone formation and increased bone resorption: Rational targets for the treatment of osteoporosis","volume":"14","author":"Seeman","year":"2003","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0725","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of Vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0730","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bone.2003.09.008","article-title":"A selective EP 4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E 2 in vivo and in vitro","volume":"34","author":"Shamir","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0735","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1073\/pnas.051599198","article-title":"Coupling of histamine H3 receptors to neuronal Na+\/H+ exchange: A novel protective mechanism in myocardial ischemia","volume":"98","author":"Silver","year":"2001","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0740","doi-asserted-by":"crossref","DOI":"10.1038\/bonekey.2013.215","article-title":"Coupling the activities of bone formation and resorption: A multitude of signals within the basic multicellular unit","volume":"3","author":"Sims","year":"2014","journal-title":"BoneKEy Reports"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0745","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2015.00041","article-title":"Coupling signals between the osteoclast and osteoblast: How are messages transmitted between these temporary visitors to the bone surface?","volume":"6","author":"Sims","year":"2015","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0750","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-014-0196-1","article-title":"Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib","volume":"12","author":"Sims","year":"2014","journal-title":"Current Osteoporosis Reports"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0755","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/en.2004-1283","article-title":"G alpha12\/G alpha13 subunits of heterotrimeric G proteins mediate parathyroid hormone activation of phospholipase D in UMR-106 osteoblastic cells","volume":"146","author":"Singh","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0760","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1074\/jbc.M115.679753","article-title":"Loss of Gs\u03b1 in the postnatal skeleton leads to low bone mass and a blunted response to anabolic parathyroid hormone therapy","volume":"291","author":"Sinha","year":"2015","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0765","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1210\/en.2003-1185","article-title":"Ligand-selective dissociation of activation and internalization of the parathyroid hormone (PTH) receptor: Conditional efficacy of PTH peptide fragments","volume":"145","author":"Sneddon","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0770","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1210\/en.2010-0930","article-title":"The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation","volume":"152","author":"Sophocleous","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0775","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1074\/jbc.M212457200","article-title":"H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2","volume":"278","author":"Sudo","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0780","doi-asserted-by":"crossref","first-page":"11281","DOI":"10.1074\/jbc.M413393200","article-title":"Parathyroid hormone receptor trafficking contributes to the activation of extracellular signal-regulated kinases but is not required for regulation of cAMP signaling","volume":"280","author":"Syme","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0785","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ncb1647","article-title":"A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation","volume":"9","author":"Takada","year":"2007","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0790","first-page":"196","article-title":"Osteoblast and osteoclast crosstalks: From OAF to Ephrin","volume":"11","author":"Tamma","year":"2012","journal-title":"Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0795","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1016\/j.bbamcr.2014.09.013","article-title":"Osteoblast differentiation and survival: A role for a 2B adenosine receptor allosteric modulators","volume":"1843","author":"Trincavelli","year":"2014","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0800","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-012-0665-8","article-title":"Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism","volume":"17","author":"Tsuruta","year":"2013","journal-title":"Clinical and Experimental Nephrology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0805","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.devcel.2006.11.003","article-title":"Noncanonical Wnt signaling through G protein-linked PKC\u03b4 activation promotes bone formation","volume":"12","author":"Tu","year":"2007","journal-title":"Developmental Cell"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0810","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0815","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0820","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL\u2013RANK\u2013OPG system in immunity, bone, and beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0825","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/hmg\/ddq462","article-title":"Disruption of PCP signaling causes limb morphogenesis and skeletal defects and may underlie Robinow syndrome and brachydactyly type B","volume":"20","author":"Wang","year":"2011","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb9999","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12167","article-title":"Structure of the human smoothened receptor 7TM bound to an antitumor agent","volume":"497","author":"Wang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0830","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1073\/pnas.1205756110","article-title":"Noncanonical GPCR signaling arising from a PTH receptor\u2013arrestin\u2013G\u03b2\u03b3 complex","volume":"110","author":"Wehbi","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0835","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1359\/jbmr.1997.12.8.1246","article-title":"Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats","volume":"12","author":"Whitfield","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0840","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02529728","article-title":"Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH-(1-31)NH2 (Ostabolin)","volume":"58","author":"Whitfield","year":"1996","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0845","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/506332","article-title":"Mutations in Wnt7A cause a range of limb malformations, including Fuhrmann syndrome and al-Awadi\/Raas-Rothschild\/Schinzel phocomelia syndrome","volume":"79","author":"Woods","year":"2006","journal-title":"The American Journal of Human Genetics"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0850","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1172\/JCI46406","article-title":"Gs\u03b1 enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice","volume":"121","author":"Wu","year":"2011","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0855","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1074\/jbc.275.6.4453","article-title":"MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1","volume":"275","author":"Xiao","year":"2000","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0860","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00599.2011","article-title":"The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice","volume":"302","author":"Xue","year":"2012","journal-title":"American Journal of Physiology - Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0865","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1073\/pnas.062053399","article-title":"Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation","volume":"99","author":"Yoshida","year":"2002","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0870","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/BJ20140668","article-title":"AP2 suppresses osteoblast differentiation and mineralization through down-regulation of Frizzled-1","volume":"465","author":"Yu","year":"2015","journal-title":"Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2017.10.015_bb0875","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nature22363","article-title":"Structure of the full-length glucagon class B G-protein-coupled receptor","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817302656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817302656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T22:32:39Z","timestamp":1750977159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725817302656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":176,"alternative-id":["S0163725817302656"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.10.015","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"G protein-coupled receptors as anabolic drug targets in osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}